RecruitingNCT06785506

Multiple-biomarker Approach for Individualized Treatment of Heart Failure with Preserved Ejection Fraction

A Dynamic, Multiple-biomarker Approach Aiming for Individualized Treatment of Heart Failure with Preserved Ejection Fraction (ADAPT-HFpEF)

Sponsor

Erasmus Medical Center

Enrollment

200 participants

Start Date

Nov 25, 2022

Study Type

OBSERVATIONAL

Conditions

Chronic Heart Failure Heart Failure With Preserved Ejection Fraction Heart Failure, Diastolic

Summary

The primary objective is to investigate the association between temporal evolutions of blood biomarkers and clinical adverse events, in order to produce a dynamic, individual, and accurate prediction model for patients with HFpEF. Moreover several secondary objectives will be investigated.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is using multiple biomarkers (measurable biological signals) to better understand and personalize treatment for people with heart failure with preserved ejection fraction (HFpEF) — a type of heart failure where the heart pumps normally but is too stiff to fill properly. **You may be eligible if...** - You are 18 or older - You have been diagnosed with HFpEF based on recognized clinical criteria - You score 6 or higher on the H2FPEF scoring system (suggesting a high probability of HFpEF) **You may NOT be eligible if...** - You have had severely reduced heart pump function (ejection fraction 40% or below) in the past - You are scheduled for heart or other surgery within 6 months - You have severely reduced kidney function (eGFR below 20) or are on dialysis - You have acute or chronic liver disease Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.